ImmunityBio Inc News - IBRX

Empower your portfolio: Real-time discussions and actionable trading ideas.

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the recent publication of preclinical data in the online...

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

All participants in the Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

The first 20 participants have been enrolled in an important national, multicenter trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV...

Form 4 - Statement of changes in beneficial ownership of securities

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Patient Reported Outcomes (PROs) based on a May 16, 2022 data cutoff in the QUILT 3.032 trial indicate stability of physical function and global...

👍️0

saigai 1 month ago

up and down.. no problem.. ima staying put

👍️0

saigai 1 month ago

we know there is a very large short position here.. i think that since the earnings post yesterday and the reaction to it that there is now very little reason to stay short,,lets see that spike

👍️0

carldfw 2 months ago

Pancreatic Cancer next!!
I like Oncolytics on that list

👍️0

Tahoe2468 2 months ago

7. ImmunityBio Inc (NASDAQ:IBRX)
Float Shorted: 40.37%

With over 53 million of its shares shorted, ImmunityBio Inc’s (NASDAQ:IBRX) short interest stands at 40.37% as of April 8.

👍️0

jondoeuk 2 months ago

From Jan 19, 2023: ''ImmunityBio also announced that it held two productive Type B meetings with the FDA in December. The first was to present the recent data and obtain guidance toward a registration pathway in metastatic pancreatic cancer.'' https://www.businesswire.com/news/home/20230119005337/en/ImmunityBio-Announces-Presentation-at-ASCO-GI-2023-of-Fully-Enrolled-Trial-in-Third-Line-and-Greater-Pancreatic-Cancer-and-Update-on-FDA-Type-B-Meetings-Regarding-Paths-to-Registration

What happened?

👍️0

jondoeuk 2 months ago

Nothing listed in the pipeline.

👍️0

Tahoe2468 2 months ago

Pancreatic Cancer next!! WOW!!

https://www.prnewswire.com/news-releases/biotechs-role-in-addressing-the-pancreatic-cancer-emergency-302089052.html

👍️0

TrendTrade2016 2 months ago

IBRX monster bio on the weekly break out

👍️0

MiamiGent 2 months ago

IBRX Friday Close $7.35+$2.24 (+43.84%)

This morning Pre-Mkt
Bid x Size
$8.13 x 2
Ask x Size
$8.20 x 212
Volume
862,349
90 Day Avg. Vol.
4,851,152

Bona fide squeeze underway. Millions of shares short are trapped.

👍️ 1

carldfw 2 months ago

Pancreatic will be even better!!In January 2023, ImmunityBio announced that it held two meetings with the FDA in December 2022 to present data and get guidance on a registration pathway for metastatic
pancreatic cancer
. The company's combination immunotherapy
, Nant Cancer Vaccine, has shown potential effectiveness in pancreatic cancer, more than doubling median overall survival (OS) compared to historical OS.

👍️0

martind18 2 months ago

That’s because IHUB is for pump and dumps.

👍️ 2

Atom Smasher 2 months ago

Good ole ihub. We have a REAL company here with a remarkable game changing cancer drug whose stock price will not only explode but retain it's stock price and no one here is even talking about it. As per my experience here several years ago.......everyone here is only interested in shells and scam companies. What a shame. That's fine. I'll be making bank. Join me if you want.......or don't. I'm not selling till it's somewhere above 40

👍️ 2

Monksdream 2 months ago

This a simple bar/volume with 60-minute intervals

The stock is actually trading counter to a recent bearish trend for most tickers according my bit of DD from the Barchart website that would be considered med tech companies
This a link for the sector that is made up 459 tickers
https://www.barchart.com/stocks/quotes/IBRX/competitors?quoteSectors=-MEBI&viewName=main&orderBy=weightedAlpha&orderDir=desc

I have a free membership so I can use the flipcharts function for the past six months of price discovery
One can observe from the sector graph at the top of the page the best time to buy any old med stock was last November
The best time to sell was at the peak last March which isn’t that long ago
I can observe the same recurring pattern in the more than 200 tickers I flipped through

👍️0

Atom Smasher 2 months ago

https://www.barchart.com/stocks/quotes/IBRX/opinion

👍️0

Monksdream 2 months ago

IBRX in the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️ 1

axelvento 2 months ago

Anktiva is the next-generation immunotherapy drug, according to ImmunityBio executive chairman Dr. Patrick Soon-Shiong: "This drug is the first drug, as far as I know, that activates the natural killer cell that talks to the T-cell and generates complete remission..." pic.twitter.com/DIVc3A8luy— Yahoo Finance (@YahooFinance) April 23, 2024

martind18 2 months ago

FDA approval!

https://www.investorsobserver.com/news/qm-news/8088196297645818

👍️0

axelvento 3 months ago

The FDA has accepted the BLA resubmission and will now review the therapy. It has set a Prescription Drug User Fee Act (PDUFA) date of 23 April 2024.

👍️0

Monksdream 3 months ago

IBRX chart

👍️0

Spideyboy 3 months ago

Just curious, having read this article from June 2022, what makes us think that they will get approval for Antikva.

My concern just stems from the bottom of the article stating.

"Other drugs are in late-stage trials in combination with BCG for the same patient population, including AstraZeneca’s Imfinzi (durvalumab) and Sesen Bio’s Vicinium (oportuzumab monatox). The FDA previously rejected Sesen Bio’s BLA for the treatment of BCG-unresponsive patients, citing multiple issues, including a lack of randomised data comparing Vicinium with an investigator’s choice of intravesical chemotherapy."
https://www.pharmaceutical-technology.com/analyst-comment/immunitybio-first-marketed-drug/?cf-view

There is no comparator in the Antikva trial with any intravesical chemotherapy either, or against anything for that matter. As it's open-label single arm trial, with only Antikva being used. Will this be enough for FDA approval?

I know the prior CRL didn't mention anything about this, but that doesn't mean it isn't a potential issue?

Looking to be convinced wrong on the above :)

👍️0

Monksdream 4 months ago

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

brogers_1 4 months ago

Research tool: https://tradingtimeline.com/ibrx.html

👍️0

martind18 6 months ago

https://www.oberlandcapital.com/news-post/immunitybio-announces-320-million-investment-by-oberland-capital/

👍️0

mick 6 months ago

https://www.otcmarkets.com/stock/IBRX

👍️0

pilotnick 6 months ago

This stock is ready to breakout, did awesome today!!

👍️0

mick 7 months ago

https://www.otcmarkets.com/stock/IBRX

👍️0

da_stock_analyst 8 months ago

#IBRX 🔥 this stock can go crazy with 30% short interest! $IBRX

👍️0

da_stock_analyst 8 months ago

#IBRX 🔥 30% short interest and gap fill possibilities for big move! $IBRX

👍️0

gail 8 months ago

yup, i see that but….

….

i didnt like how each time it runs, they yank it right back down, so i moved on but im happy it ran for you some. just be careful, they dont seem to last long.

👍️0

Jess070283 8 months ago

Just warming up…

👍️0

crudeoil24 8 months ago

News > Up 29%today > The FDA accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete.

👍️0

gail 8 months ago

then the usual dump, lol.

👍️0

gail 8 months ago

nice move so far today

👍️0

BoilerRoom 8 months ago

$IBRX looks interesting

👍️0

gail 8 months ago

hopped in on this dip. i like the run it had last time.

👍️0

Monksdream 9 months ago

IBRX under $2

👍️0

mick 9 months ago

https://www.otcmarkets.com/stock/IBRX

👍️0

mick 10 months ago

https://otcbb.swingtradebot.com/equities/IBRX

👍️0

mick 11 months ago

IBRX
ImmunityBio Inc
2.72
0.09 (3.42%)
Volume: 1,135,051
Day Range: 2.60 - 2.75
Last Trade Time: 7:59:29 PM EDT

👍️0

mick 12 months ago

IBRX
ImmunityBio Inc
2.69
-0.12 (-4.27%)
Volume: 6,333,343
Day Range: 2.63 - 2.85
Last Trade Time: 7:51:23 PM EDT

👍️0

mick 1 year ago

IBRX
ImmunityBio Inc
2.57
0.19 (7.98%)
Volume: 2,354,869
Day Range: 2.35 - 2.57
Last Trade Time: 7:56:03 PM EDT

👍️0

BEIJING BILL 1 year ago

IBRX an offering done right. bonzzzaaaa

👍️0

da_stock_analyst 1 year ago

#IBRX ?? gap fill after 3.3? Trade opportunity? $IBRX

👍️0

TheFinalCD 1 year ago

-55% $IBRX received FDA CRL

Recall position was a catalyst play and not an investment which I clearly outlined in my thread.

Multiple times I tweeted that I closed my full position as stock appreciated a lot from entry point (Below $2) to almost 6+

Risk management is important for…— Pharmdca (@Pharmdca) May 11, 2023

👍️0

surf1944 1 year ago

The shorts are actually in IBRX and for a reason:

Total Cash (mrq) 107.18M
Total Cash Per Share (mrq) 0.25
Total Debt (mrq) 725.19M

https://www.nasdaq.com/market-activity/stocks/ibrx/short-interest

https://www.nasdaq.com/market-activity/stocks/ibrx/financials

👍️0

Cosa 1 year ago

Ouch! Sorry to anyone holding.

👍️0

LowFloatLopes 1 year ago

FDA denied

👍️0

da_stock_analyst 1 year ago

#IBRX ?? Will it pullback soon? Price action analysis $IBRX

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ImmunityBio Inc (IBRX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IBRX News

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Form 4 - Statement of changes in beneficial ownership of securities

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IBRX Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ImmunityBio Inc (IBRX) News

ImmunityBio Inc (IBRX)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IBRX News

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Form 4 - Statement of changes in beneficial ownership of securities

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IBRX Discussion

Your Recent History

Company

Business

Popular

Get The App